Clinical trial · Interventional
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient (Pemb-HT)
NCT05368207CI-TRIAL-00115536Pemb-HTcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Small Cell Carcinoma, Hypercalcaemic Type | Small Cell Neuroendocrine Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pembrolizumab | Drug | Pembrolizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Pembrolizumab
- description
- Pembrolizumab will be given as an intravenous infusion at 200 mg, every 6 weeks, for 6 cycles.
- interventionNames
- Drug: Pembrolizumab
Primary outcomes (1)
- measure
- Progression free survival
- timeFrame
- 2 years
- description
- Determined by CT scans
Secondary outcomes (3)
- measure
- overall performance status
- timeFrame
- 2 years
- description
- Eastern cooperative oncology group (ECOG) score, patient-reported symptoms as well as objective measurements by CT scans.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) Exclusion Criteria: * N/A
References
Publications (0)
Data not yet available
No reference posted for this study.